SOL 924Alternative Names: SOL924
Latest Information Update: 08 Dec 2015
At a glance
- Originator Solural Pharma
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase I Unspecified
Most Recent Events
- 02 Dec 2014 Phase-I clinical trials in Undefined indication in Denmark (PO)